By disease in patients, is a small but some hospitals were already prescribing patients ahead of the clinical site in anticipation that there is high. But now excluded from prescription for pay from entering that the burden of costs and likely to be consideration of the prescription side effects.

According to the pharmaceutical industry on the 16th, RET (REarranged drug transmission) target treatments currently approved in Korea are Lilly's Retevmo and Roche's Gavreto. Retevmo is applied to adult patients with metastatic RET fusion-positive non-small cell lung cancer, adults with progressive or metastatic RET-mutant thyroid cancer and children over 12 years of age who are not compliant with radiation Iodin